Core Unit for Molecular Tumor Diagnostics (CMTD)

The Core Unit for Molecular Tumor Diagnostics (CMTD) was recently established at the NCT partner site Dresden. The CMTD is jointly headed by the Department of Pathology (Prof. Dr. Gustavo Baretton) and the Department for Clinical Genetics (Prof. Dr. Evelin Schröck). It is located at the Department of Pathology. The CMTD is a central research infrastructure providing NGS-based molecular characterization of sporadic and hereditary tumors within translational research projects and clinical studies. Our goal is the rapid translation of molecular information into the clinic by applying dedicated multi-genepanels on all NCT-patients at the partner site Dresden.

The CMTD services include the following:

Complete processing from tumor samples and liquid biopsies to clinical report: Evaluation of tumor samples by a pathologist (including assessment of tumor content and microdissection). DNA/RNA preparation with quality assessment. Enrichment and Sequencing on the NextSeq500 platform. Data analyzation and interpretation by a board certified human geneticist (Dr. med. Laura Gieldon) and a board certified molecular pathologist (OÄ PD Dr. med. Daniela Aust).
Additional molecular genetic analyzes as well as immunohistochemistry and Fluorescent-in situ-Hybridization (FISH)
Development of customized multi-Genepanels for user specific applications
Consulting for research projects and support with grant applications
Access to specialized technologies in cooperation (DNA/RNA quality assessment using Fragmentanalyzer; NGS on the NextSeq500 platform,...)